(SRTA) Strata Critical Medical - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 502m USD | Total Return: 73.9% in 12m
Avg Turnover: 5.57M
Qual. Beats: 0
Rev. Trend: 75.0%
Warnings
High Debt/EBITDA (9.7) with thin interest coverage (-12.3)
High Debt while negative Cash Flow
Interest Coverage Ratio -12.3 is critical
Beneish M-Score -1.26 > -1.5 - likely earnings manipulation
Altman Z'' -3.31 < 1.0 - financial distress zone
Extended 1w Volatile
Tailwinds
Idiosyncratic Leader
Strata Critical Medical, Inc. (NASDAQ: SRTA) specializes in time-sensitive logistics and clinical support for the U.S. healthcare sector. The company operates through two primary segments: Logistics, which manages the air and ground transport of human organs and transplant teams, and Clinical, which provides specialized medical procedures such as organ recovery and extracorporeal membrane oxygenation (ECMO). Formerly known as Blade Air Mobility, Inc., the firm rebranded in August 2025 to reflect its focus on medical infrastructure.
The company operates within the specialized healthcare logistics sector, where high barriers to entry exist due to the complex regulatory requirements for handling biological materials. Its business model relies on a combination of asset-light transportation coordination and highly skilled clinical staffing to support transplant centers and hospitals. For a deeper look into the companys valuation metrics, investors may find ValueRay worth a visit. Headquartered in New York, Strata Critical Medical serves as a critical link in the organ transplant supply chain by integrating surgical recovery services with rapid delivery networks.
- Organ transplant volume growth directly impacts core logistics and clinical services revenue
- Expansion of normothermic regional perfusion services drives higher margin clinical segment growth
- High fixed costs for aircraft and medical equipment pressure quarterly operating margins
- Federal regulatory changes to organ procurement organization standards affect long-term case volume
- Availability of specialized perfusion staffing influences the capacity to meet hospital demand
| Net Income: 50.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA -6.20 > 1.0 |
| NWC/Revenue: 40.59% < 20% (prev 51.86%; Δ -11.28% < -1%) |
| CFO/TA -0.12 > 3% & CFO -40.8m > Net Income 50.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.2m) vs 12m ago 12.86% < -2% |
| Gross Margin: 20.52% > 18% (prev 0.24%; Δ 2.03k% > 0.5%) |
| Asset Turnover: 87.96% > 50% (prev 100.4%; Δ -12.42% > 0%) |
| Interest Coverage Ratio: -12.33 > 6 (EBITDA TTM -5.59m / Interest Expense TTM 1.23m) |
| A: 0.32 (Total Current Assets 124.1m - Total Current Liabilities 20.9m) / Total Assets 327.6m |
| B: -0.44 (Retained Earnings -143.4m / Total Assets 327.6m) |
| C: -0.05 (EBIT TTM -15.1m / Avg Total Assets 289.1m) |
| D: -3.42 (Book Value of Equity -143.4m / Total Liabilities 41.9m) |
| Altman-Z'' = -3.31 = D |
| DSRI: 1.77 (Receivables 39.6m/22.1m, Revenue 254.3m/251.5m) |
| GMI: 1.18 (GM 20.52% / 24.16%) |
| AQI: 2.14 (AQ_t 0.49 / AQ_t-1 0.23) |
| SGI: 1.01 (Revenue 254.3m / 251.5m) |
| TATA: 0.28 (NI 50.8m - CFO -40.8m) / TA 327.6m) |
| Beneish M = -1.26 (Cap -4..+1) = D |
As of May 27, 2026, the stock is trading at USD 6.14 with a total of 943,208 shares traded.
Over the past week, the price has changed by +14.34%,
over one month by +24.04%,
over three months by +38.60% and
over the past year by +73.94%.
Strata Critical Medical has no consensus analysts rating.
P/E Forward = 138.8889
P/S = 2.1956
P/B = 1.7549
Revenue TTM = 254.3m USD
EBIT TTM = -15.1m USD
EBITDA TTM = -5.59m USD
Long Term Debt = 3.48m USD (estimated: total debt 4.47m - short term 987k)
Short Term Debt = 987k USD (from shortTermDebt, last quarter)
Debt = 4.47m USD (from shortLongTermDebtTotal, last quarter) (leases 4.47m already included)
Net Debt = -54.3m USD (calculated: Debt 4.47m - CCE 58.8m)
Enterprise Value = 447.5m USD (501.9m + Debt 4.47m - CCE 58.8m)
Interest Coverage Ratio = -12.33 (Ebit TTM -15.1m / Interest Expense TTM 1.23m)
EV/FCF = -8.29x (Enterprise Value 447.5m / FCF TTM -54.0m)
FCF Yield = -12.06% (FCF TTM -54.0m / Enterprise Value 447.5m)
FCF Margin = -21.23% (FCF TTM -54.0m / Revenue TTM 254.3m)
Net Margin = 19.97% (Net Income TTM 50.8m / Revenue TTM 254.3m)
Gross Margin = 20.52% ((Revenue TTM 254.3m - Cost of Revenue TTM 202.1m) / Revenue TTM)
Gross Margin QoQ = 18.74% (prev 15.26%)
Tobins Q-Ratio = 1.37 (Enterprise Value 447.5m / Total Assets 327.6m)
Interest Expense / Debt = 27.48% (Interest Expense 1.23m / Debt 4.47m)
Taxrate = 10.32% (248k / 2.40m)
NOPAT = -13.6m (EBIT -15.1m * (1 - 10.32%)) [loss with tax shield]
Current Ratio = 5.93 (Total Current Assets 124.1m / Total Current Liabilities 20.9m)
Debt / Equity = 0.02 (Debt 4.47m / totalStockholderEquity, last quarter 285.7m)
Debt / EBITDA = 9.72 (negative EBITDA) (Net Debt -54.3m / EBITDA -5.59m)
Debt / FCF = 1.01 (negative FCF - burning cash) (Net Debt -54.3m / FCF TTM -54.0m)
Total Stockholder Equity = 267.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.56% (Net Income 50.8m / Total Assets 327.6m)
RoE = 12.35% (Net Income TTM 50.8m / Total Stockholder Equity 411.1m)
RoCE = -3.65% (EBIT -15.1m / Capital Employed (Equity 411.1m + L.T.Debt 3.48m))
RoIC = -5.45% (negative operating profit) (NOPAT -13.6m / Invested Capital 248.9m)
WACC = 13.02% (E(501.9m)/V(506.3m) * Re(12.92%) + D(4.47m)/V(506.3m) * Rd(27.48%) * (1-Tc(0.10)))
Discount Rate = 12.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 8.75%
[DCF] Fair Price = unknown (Cash Flow -54.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.16 | # QB: 0
Revenue Correlation: 74.96 | Revenue CAGR: 7.20% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=+0.00% | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.03 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=-0.14 | Chg30d=+0.00% | Revisions=-20% | GrowthEPS=+54.2% | GrowthRev=+37.6%
EPS next Year (2027-12-31): EPS=-0.01 | Chg30d=N/A | Revisions=-20% | GrowthEPS=+84.6% | GrowthRev=+10.3%
[Analyst] Revisions Ratio: -20%